Challenges Linger as Chinese Firms Kick Off R&D Race (Pt.2)
This article was originally published in PharmAsia News
China’s pharmaceutical industry is entering a critical period of transformation as it is losing its traditional price competitiveness in the international market and is now looking more to develop its potential as a force in original R&D. New development models and innovative firms have emerged in the country in recent years, some of which shared their strategies and challenges at a recent meeting in Shanghai.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.